Efficacy and safety of finerenone with SGLT2i in IgA nephropathy
Nephrology Dialysis Transplantation · 29.05.2026 · 41 (6) · 1138-1146
DOI: 10.1093/ndt/gfaf244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.11.2025. Verfasst von Yanhong Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephropathy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Sodium-Glucose Transporter 2 Inhibitors, Proteinuria, Naphthyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
This study aimed to compare the renal protective effects and safety profile of finerenone plus sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy versus monotherapy in patients with immunoglobulin A (IgA) nephropathy.
Methods
The retrospective study evaluated 76 patients with biopsy-proven IgA nephropathy at the First Affiliated Hospital of Zhengzhou University (2023–24). Participants were divided into three groups: finerenone plus SGLT2i group (n = 26), finerenone monotherapy group (n = 32) and SGLT2i monotherapy group (n = 18). Changes in urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate at 3 and 6 months were evaluated. Safety assessments focused on hyperkalemia incidence and treatment-emergent adverse events.
Results
The combination therapy demonstrated superior proteinuria reduction compared with monotherapies, with median UPCR reductions of 40.89% at Month 3 and 54.62% at Month 6 versus 23.72%/30.88% (finerenone) and 24.69%/24.69% (SGLT2i) (all P < .05). Significantly more patients achieved ≥50% UPCR reduction in the finerenone plus SGLT2i group at Month 6 (53.8% vs 25.0% and 22.2%, P = .033). Logistic regression analysis demonstrated adjusted odds ratios ranging from 3.87 to 18.90 for finerenone plus SGLT2i therapy achieving ≥50% proteinuria reduction (all P < .05). Renal function parameters remained stable in all treatment groups without significant intergroup differences (all P > .05). The safety profile showed comparable hyperkalemia incidence rates between groups (P = .332). No severe adverse events or treatment withdrawals attributable to hyperkalemia were observed.
Conclusion
Our study shows that combined finerenone-SGLT2i therapy has a more rapid and superior proteinuria reduction versus monotherapy in IgA nephropathy, with preserved renal function and good safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephropathy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Guo, Y., Zhao, S., Dong, Y., Wang, Y., Wang, L., Li, Q., Zhai, Z., Yu, L., & Tang, L. (2026). Efficacy and safety of finerenone with SGLT2i in IgA nephropathy. Nephrology Dialysis Transplantation, 41(6), 1138-1146. https://doi.org/10.1093/ndt/gfaf244
Vancouver
Guo Y, Zhao S, Dong Y, Wang Y, Wang L, Li Q, et al. Efficacy and safety of finerenone with SGLT2i in IgA nephropathy. Nephrology Dialysis Transplantation. 2026;41(6):1138-1146. doi:10.1093/ndt/gfaf244
BibTeX
@article{Guo2026,
author = {Guo, Yanhong and Zhao, Silu and Dong, Yanna and Wang, Yulin and Wang, Liuwei and Li, Qiuhong and Zhai, Zihan and Yu, Lu and Tang, Lin},
title = {Efficacy and safety of finerenone with SGLT2i in IgA nephropathy},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {6},
pages = {1138--1146},
doi = {10.1093/ndt/gfaf244}
}
EUVIMED